We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+5.39%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
-$169M
Cap. Flow
-$49.5M
Cap. Flow %
-3.29%
Top 10 Hldgs %
63.08%
Holding
56
New
8
Increased
10
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$57.8M
2
APLS
Apellis Pharmaceuticals
APLS
+$27M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$25.5M
4
BBIO icon
BridgeBio Pharma
BBIO
+$20.9M
5
ANTX icon
AN2 Therapeutics
ANTX
+$15.7M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$167M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$58.8M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.2M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$10.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$6.15M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
2 Miscellaneous 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIRM icon
1
Mirum Pharmaceuticals
MIRM
$5.94B
$204M 13.58%
6,470,392
+2,110,285
+48% +$57.8M
HLVX
2
DELISTED
HilleVax
HLVX
$132M 8.74%
9,781,472
– –
KRYS icon
3
Krystal Biotech
KRYS
$10.4B
$115M 7.62%
988,460
-1,800
-0.2% -$220K
NAMS icon
4
NewAmsterdam Pharma
NAMS
$3.1B
$112M 7.45%
12,131,705
+1,259,902
+12% +$13.6M
PHAT icon
5
Phathom Pharmaceuticals
PHAT
$743M
$105M 6.96%
10,109,279
– –
BBIO icon
6
BridgeBio Pharma
BBIO
$15B
$71.9M 4.77%
2,725,949
+737,073
+37% +$20.9M
PCVX icon
7
Vaxcyte
PCVX
$8.9B
$59.4M 3.94%
1,164,405
– –
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.38B
$54.4M 3.61%
2,371,304
+204,082
+9% +$4.57M
VRNA
9
DELISTED
Verona Pharma
VRNA
$49.1M 3.26%
3,014,349
+70,000
+2% +$1.35M
CRNX icon
10
Crinetics Pharmaceuticals
CRNX
$9B
$47.3M 3.14%
1,589,931
+175,108
+12% +$3.61M
ARQT icon
11
Arcutis Biotherapeutics
ARQT
$2.99B
$46.1M 3.06%
8,684,232
– –
ALPN
12
DELISTED
Alpine Immune Sciences Inc
ALPN
$34.2M 2.27%
2,985,757
– –
TARS icon
13
Tarsus Pharmaceuticals
TARS
$3.15B
$31.8M 2.11%
1,787,527
– –
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
$31.2M 2.07%
3,238,859
– –
IRON icon
15
Disc Medicine
IRON
$3.07B
$30.8M 2.04%
655,000
– –
RCKT icon
16
Rocket Pharmaceuticals
RCKT
$424M
$28.7M 1.91%
+1,403,013
New +$25.5M
RVMD icon
17
Revolution Medicines
RVMD
$44.6B
$27.6M 1.83%
997,455
+142,971
+17% +$4.24M
APLS
18
DELISTED
Apellis Pharmaceuticals
APLS
$23.4M 1.55%
+614,043
New +$27M
ANTX icon
19
AN2 Therapeutics
ANTX
$211M
$22.3M 1.48%
+1,388,889
New +$15.7M
MRUS
20
DELISTED
Merus
MRUS
$17.6M 1.17%
746,479
– –
JBIO
21
Jade Biosciences
JBIO
$1.33B
$16.4M 1.09%
34,425
+6,000
+21% +$3.25M
ANAB icon
22
AnaptysBio
ANAB
$1.67B
$16.2M 1.07%
899,700
– –
SVRA icon
23
Savara
SVRA
$1.08B
$15.1M 1%
+4,000,000
New +$14.3M
TRVI icon
24
Trevi Therapeutics
TRVI
$2.39B
$15M 1%
6,881,090
– –
COGT icon
25
Cogent Biosciences
COGT
$6.02B
$14.6M 0.97%
1,501,383
– –
1
2 3

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q3 2023 Portfolio in Review

As of Q3 2023, Frazier Life Sciences Management held 56 positions worth $1.51B, down 10% from $1.67B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Frazier Life Sciences Management withdrew a net $49.5M in Q3 2023, closing 4 positions and reducing 5 holdings. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $167M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Frazier Life Sciences Management opened a new position in Apellis Pharmaceuticals worth $23.4M.

  • Frazier Life Sciences Management's largest Q3 2023 buy was Apellis Pharmaceuticals: 614,043 shares worth $23.4M.
  • Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q3 2023, an estimated $57.8M increase.
  • Frazier Life Sciences Management's biggest Q3 2023 reduction was Syndax Pharmaceuticals, cutting an estimated $58.8M.
  • Frazier Life Sciences Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $167M.
  • Frazier Life Sciences Management's ten largest holdings make up 63% of its $1.51B portfolio in Q3 2023.
  • Frazier Life Sciences Management opened 8 new positions and closed 4 in Q3 2023.
  • Frazier Life Sciences Management's portfolio value fell 10% quarter-over-quarter to $1.51B.

Based on Frazier Life Sciences Management's 13F filing for Q3 2023, filed 14 Nov 2023.